#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2948	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2364	361.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1711	1711	T	444	T,C	409,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2948	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2364	361.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1445	1445	C	425	C	382	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2948	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2364	361.3	0	HET	.	.	.	A69G	.	69	69	A	330	330	A	412	A,G	217,167	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2948	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2364	361.3	0	HET	.	.	.	A885G	.	885	885	A	1146	1146	A	467	A,G	308,115	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4466	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3992	334.8	0	.	n	.	0	C1176T	SNP	1176	1176	C	1767	1767	T	346	T	316	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4466	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3992	334.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1928	1928	A	373	A	341	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4466	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3992	334.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2562	2562	C	425	C,T,A	387,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4466	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3992	334.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2636	2636	A	427	A,C	382,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4466	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3992	334.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3188	3188	C	387	C,T	346,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	440	folP	852	852	99.88	folP.l15.c4.ctg.1	2069	63.6	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1064	1066	AAA	89;89;90	A;A;A	82;83;83	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	440	folP	852	852	99.88	folP.l15.c4.ctg.1	2069	63.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1295	1297	AGC	91;91;92	A;G;C	83;84;85	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	990	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	4111	72.2	0	.	p	.	0	K261del	DEL	781	781	A	1452	1452	A	101	A	87	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	990	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	4111	72.2	1	SNP	p	S91F	0	.	.	271	273	TCC	942	944	TCC	102;102;102	T;C;C	93;95;95	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	990	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	4111	72.2	1	SNP	p	D95N	0	.	.	283	285	GAC	954	956	GAC	104;105;105	G;A;C	96;97;98	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	990	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	4111	72.2	1	SNP	p	D95G	0	.	.	283	285	GAC	954	956	GAC	104;105;105	G;A;C	96;97;98	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	442	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1660	79.1	1	SNP	p	G45D	0	.	.	133	135	GGC	663	665	GGC	132;132;131	G;G;C	117;118;119	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	294	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1565	56.3	0	.	n	.	0	A197.	DEL	197	197	A	836	836	A	114	A	103	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	926	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3647	76.2	1	SNP	p	D86N	0	.	.	256	258	GAC	1028	1030	GAC	104;104;104	G;A;C	86;89;89	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	926	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3647	76.2	1	SNP	p	S87I	0	.	.	259	261	AGT	1031	1033	AGT	104;104;104	A;G;T	86;91;91	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	926	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3647	76.2	1	SNP	p	S87W	0	.	.	259	261	AGT	1031	1033	AGT	104;104;104	A;G;T	86;91;91	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	926	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3647	76.2	1	SNP	p	S87R	0	.	.	259	261	AGT	1031	1033	AGT	104;104;104	A;G;T	86;91;91	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	926	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3647	76.2	1	SNP	p	S88P	0	.	.	262	264	TCC	1034	1036	TCC	105;105;106	T;C;C	94;92;95	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	902	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3268	82.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1852	1854	GGC	107;106;106	G;G;C	96;94;92	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1572	1574	GCA	104;105;105	G,T;C,A;A,C	92,1;91,1;94,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1575	1577	ATC	104;103;102	A;T;C	88;91;94	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1587	1589	GTG	104;104;105	G;T;G	93;90;93	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1587	1589	GTG	104;104;105	G;T;G	93;90;93	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2091	2093	ACC	101;102;104	A,C;C;C	90,1;91;92	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2145	2147	GCG	100;99;98	G;C,T;G,A	82;73,1;77,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2145	2147	GCG	100;99;98	G;C,T;G,A	82;73,1;77,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2268	2270	GGC	105;105;105	G,C;G;C	92,1;92;90	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2277	2279	GGC	105;105;104	G;G;C,T	91;93;91,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2949	76.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2295	2297	CTG	104;103;104	C;T;G,A	90;87;87,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1108	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3495	94.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1850	1852	CCG	108;109;108	C;C;G	94;100;95	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	438	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2382	55.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	809	809	C	78	C	74	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1313	1315	AAT	16;16;16	A;A;T	14;14;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1316	1318	AAT	16;16;16	A;A;T	15;13;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1340	1342	GCA	14;14;14	G;C;A	14;13;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1363	1365	GTA	14;14;13	G;T;A	14;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1369	1371	AAC	13;13;13	A;A;C	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1373	1377	TGGCG	13;13;13;13;13	T;G;G;C;G	13;13;13;13;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1379	1381	GCT	13;13;13	G;C;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1439	1441	TTA	11;11;11	T;T;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1484	1486	CAT	10;10;10	C;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1487	1489	AGT	10;10;10	A;G;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	84	porB1a	984	296	90.33	porB1a.l15.c4.ctg.1	1584	14.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1496	1498	TAC	10;11;11	T;A;C	10;10;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	511	513	GAA	138;139;139	G;A;A	125;126;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	799	801	GAT	140;138;138	G;A;T	123;123;124	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	P175L	NONSYN	523	525	CCA	922	924	TTA	136;137;139	T;T;A	125;128;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	D212N	NONSYN	634	636	GAT	1033	1035	AAT	134;134;134	A,G;A;T	119,1;119;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1051	1053	GTC	134;134;136	G;T,G;C	122;123,1;126	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1063	1065	TCT	136;136;137	T;C;T	126;129;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1381	1383	GCA	132;132;132	G,T;C,G;A,T	113,1;115,1;113,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	1	SNP	p	G120K	1	.	.	358	360	AAG	757	759	AAG	144;142;141	A;A;G	130;131;128	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	1	SNP	p	A121D	1	.	.	361	363	GAC	760	762	GAC	141;140;140	G;A;C	128;129;130	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	710	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1723	119.2	1	SNP	p	D121N	0	.	.	361	363	GAC	760	762	GAC	141;140;140	G;A;C	128;129;130	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1924	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5406	106.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2257	2259	AAT	107;107;107	A;A;T	99;98;100	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	322	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1520	63.4	1	SNP	p	V57M	1	.	.	169	171	ATG	876	878	ATG	116;115;114	A,C;T;G	102,1;104;102	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
